Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial

COMMENTED

Thyroid

Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Front Endocrinol (Lausanne)

Czarniecka A, Zeman M, Wozniak G, Maciejewski A, Stobiecka E, Chmielik E, Oczko-Wojciechowska M, Krajewska J, Handkiewicz-Junak D, Jarzab B

doi: 10.3389/fendo.2021.718833

COMMENTED

Thyroid

Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter, phase II trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Thyroid

Yansong L, Yang H, Ding Y, Cheng Y, Shi F, Tan J, Deng Z, Chen Z, Wang R, Ji Q, Huang R, Li L

doi: 10.1089/thy.2020.0235

COMMENTED

Type 1 DiabetesGlycemic Control

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial

Lancet Diabetes Endocrinol.

Bosi E, Choudhary P, de Valk HW, Lablanche S, Castañeda J, de Portu S, Da Silva J, Ré R, Vorrink-de Groot L, Shin J, Kaufman FR, Cohen O, SMILE Study Group.

doi: 10.1016/

COMMENTED

Obesity and Bariatric Surgery

Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial

Lancet.

Robert M, Espalieu P, Pelascini E, Caiazzo R, Sterkers A, Khamphommala L, Poghosyan T, Chevallier JM, Malherbe V, Chouillard E, Reche F, Torcivia A, Maucort-Boulch D, Bin-Dorel S, Langlois-Jacques C, Delaunay D, Pattou F, Disse E

doi: 10.1016/S0140-6736(19)30475-1.

Diabetes - GeneralType 2 Diabetes

Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial

Lancet Diabetes Endocrinol.

Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, Peng L, Hodish I, Bodnar T, Wesorick D, Balakrishnan V, Osei K, Umpierrez GE

doi: 10.1016/

COMMENTED

Type 2 Diabetes

Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial

PLoS Med.

Ruscitti P, Masedu F, Alvaro S, Airò P, Battafarano N, Cantarini L, Cantatore FP, Carlino G, D'Abrosca V, Frassi M, Frediani B, Iacono D, Liakouli V, Maggio R, Mulè R, Pantano I, Prevete I, Sinigaglia L, Valenti M, Viapiana O, Cipriani P, Giacomelli R

doi: 10.1371/

Type 2 Diabetes

Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus®) in Chinese adults with type 2 diabetes mellitus: A Phase III, randomised, open-label, controlled trial

Diabetes Obes Metab

Feng W, Chen W, Jiang S, Du L, Zhu D

doi: 10.1111/dom.14392

COMMENTED

Type 2 Diabetes

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

Lancet Diabetes Endocrinol.

Aroda VR, González-Galvez G, Grøn R, Halladin N, Haluzík M, Jermendy G, Kok A, Őrsy P, Sabbah M, Sesti G, Silver R

doi: 10.1016/S2213-

Further Publications

Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema

Br J Ophthalmol.

Mehta H, Fraser-Bell S, Nguyen V, Lim LL, Gillies MC

doi: 10.1136/

Related content

Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015

Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter, phase II trial

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial

Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial

Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial

Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial

Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus®) in Chinese adults with type 2 diabetes mellitus: A Phase III, randomised, open-label, controlled trial

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema